Takeda initiates continuation study of Zasocitinib for Psoriatic Arthritis
Takeda is conducting a continuation study of Zasocitinib in adults with Psoriatic Arthritis to assess long-term safety and efficacy.
Company
Pharmaceutical intelligence for Takeda with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.